CN1914319B - 色谱分离核酸混合物的方法 - Google Patents
色谱分离核酸混合物的方法 Download PDFInfo
- Publication number
- CN1914319B CN1914319B CN2005800037645A CN200580003764A CN1914319B CN 1914319 B CN1914319 B CN 1914319B CN 2005800037645 A CN2005800037645 A CN 2005800037645A CN 200580003764 A CN200580003764 A CN 200580003764A CN 1914319 B CN1914319 B CN 1914319B
- Authority
- CN
- China
- Prior art keywords
- chromatography
- value
- nucleic acid
- amino
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 65
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 41
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 41
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 238000013375 chromatographic separation Methods 0.000 title abstract description 8
- 239000013612 plasmid Substances 0.000 claims abstract description 50
- 238000000746 purification Methods 0.000 claims abstract description 5
- 108020004414 DNA Proteins 0.000 claims description 49
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 44
- 102000053602 DNA Human genes 0.000 claims description 43
- -1 alkali metal salts Chemical class 0.000 claims description 32
- 238000004587 chromatography analysis Methods 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 23
- 238000005406 washing Methods 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 19
- 229910052783 alkali metal Inorganic materials 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 150000001721 carbon Chemical group 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 15
- 239000012876 carrier material Substances 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000003368 amide group Chemical group 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000003700 epoxy group Chemical group 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 229910001508 alkali metal halide Inorganic materials 0.000 claims description 5
- 150000008045 alkali metal halides Chemical group 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 150000001340 alkali metals Chemical class 0.000 claims description 4
- 229910001615 alkaline earth metal halide Inorganic materials 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 2
- 229920000936 Agarose Polymers 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 2
- 229920005990 polystyrene resin Polymers 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 2
- 125000005208 trialkylammonium group Chemical group 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 238000001415 gene therapy Methods 0.000 abstract description 6
- 238000000926 separation method Methods 0.000 abstract description 3
- 102000006382 Ribonucleases Human genes 0.000 abstract 1
- 108010083644 Ribonucleases Proteins 0.000 abstract 1
- 238000011239 genetic vaccination Methods 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 8
- 238000005336 cracking Methods 0.000 description 8
- 235000011056 potassium acetate Nutrition 0.000 description 8
- 108020004682 Single-Stranded DNA Proteins 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 210000000172 cytosol Anatomy 0.000 description 6
- 238000013016 damping Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000007844 bleaching agent Substances 0.000 description 4
- 230000003139 buffering effect Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 108091092562 ribozyme Proteins 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 229920004929 Triton X-114 Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (27)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04001864A EP1559783A1 (de) | 2004-01-29 | 2004-01-29 | Verfahren zur chromatographischen Trennung eines Nukleinsäuregemisches |
EP04001864.0 | 2004-01-29 | ||
PCT/EP2005/000693 WO2005073376A1 (de) | 2004-01-29 | 2005-01-25 | Verfahren zur chromatographischen trennung eines nukleinsäuregemisches |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1914319A CN1914319A (zh) | 2007-02-14 |
CN1914319B true CN1914319B (zh) | 2010-06-09 |
Family
ID=34639400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800037645A Active CN1914319B (zh) | 2004-01-29 | 2005-01-25 | 色谱分离核酸混合物的方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20070275920A1 (zh) |
EP (2) | EP1559783A1 (zh) |
JP (1) | JP2007519407A (zh) |
CN (1) | CN1914319B (zh) |
AU (1) | AU2005209389A1 (zh) |
WO (1) | WO2005073376A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9458452B2 (en) | 2010-11-09 | 2016-10-04 | Qiagen Gmbh | Method and device for isolating and purifying double-stranded nucleic acids |
WO2014047141A1 (en) * | 2012-09-19 | 2014-03-27 | Beckman Coulter, Inc. | USE OF DIVALENT IONS, PROTEASES, DETERGENTS, AND LOW pH IN THE EXTRACTION OF NUCLEIC ACIDS |
CN104232687A (zh) * | 2014-09-17 | 2014-12-24 | 许瑞安 | 一种重组腺相关病毒rAAV载体的分离纯化方法 |
GB201709531D0 (en) * | 2017-06-15 | 2017-08-02 | Ge Healthcare Bio Sciences Ab | Method and apparatus for determining one or more buffer composition recipes |
US11198879B2 (en) * | 2018-10-25 | 2021-12-14 | Viet Nam National University Ho Chi Minh City | Mixture of cell extract and method for site-directed cloning |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995021177A1 (de) * | 1994-02-07 | 1995-08-10 | Qiagen Gmbh | Verfahren zur herstellung endotoxinfreier oder an endotoxin abgereicherter nucleinsäuren und/oder oligonucleotide für die gentherapie |
US5990301A (en) * | 1994-02-07 | 1999-11-23 | Qiagen Gmbh | Process for the separation and purification of nucleic acids from biological sources |
WO2001038516A1 (en) * | 1999-11-25 | 2001-05-31 | Amersham Biosciences Ab | Method for purifying plasmid dna by anion-exchange chromatography |
CN1348332A (zh) * | 1999-03-03 | 2002-05-08 | 宾夕法尼亚大学理事会 | 疫苗和基因治疗组合物以及其制备和使用方法 |
CN1413300A (zh) * | 1999-12-23 | 2003-04-23 | 蒂特根博士生物技术公司 | 层析材料以及使用该材料的方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3639949A1 (de) * | 1986-11-22 | 1988-06-09 | Diagen Inst Molekularbio | Verfahren zur trennung von langkettigen nukleinsaeuren |
DE4432654C2 (de) * | 1994-09-14 | 1998-03-26 | Qiagen Gmbh | Verfahren zur Isolierung von Nukleinsäuren aus natürlichen Quellen |
US5981735A (en) * | 1996-02-12 | 1999-11-09 | Cobra Therapeutics Limited | Method of plasmid DNA production and purification |
US6406892B1 (en) * | 2001-05-23 | 2002-06-18 | Bio-Rad Laboratories, Inc. | Acetate-free purification of plasmid DNA on hydroxyapatite |
-
2004
- 2004-01-29 EP EP04001864A patent/EP1559783A1/de not_active Withdrawn
-
2005
- 2005-01-25 EP EP05706998A patent/EP1713910A1/de not_active Withdrawn
- 2005-01-25 JP JP2006550069A patent/JP2007519407A/ja active Pending
- 2005-01-25 WO PCT/EP2005/000693 patent/WO2005073376A1/de active Application Filing
- 2005-01-25 US US10/587,892 patent/US20070275920A1/en not_active Abandoned
- 2005-01-25 AU AU2005209389A patent/AU2005209389A1/en not_active Abandoned
- 2005-01-25 CN CN2005800037645A patent/CN1914319B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995021177A1 (de) * | 1994-02-07 | 1995-08-10 | Qiagen Gmbh | Verfahren zur herstellung endotoxinfreier oder an endotoxin abgereicherter nucleinsäuren und/oder oligonucleotide für die gentherapie |
US5990301A (en) * | 1994-02-07 | 1999-11-23 | Qiagen Gmbh | Process for the separation and purification of nucleic acids from biological sources |
CN1348332A (zh) * | 1999-03-03 | 2002-05-08 | 宾夕法尼亚大学理事会 | 疫苗和基因治疗组合物以及其制备和使用方法 |
WO2001038516A1 (en) * | 1999-11-25 | 2001-05-31 | Amersham Biosciences Ab | Method for purifying plasmid dna by anion-exchange chromatography |
CN1413300A (zh) * | 1999-12-23 | 2003-04-23 | 蒂特根博士生物技术公司 | 层析材料以及使用该材料的方法 |
Non-Patent Citations (4)
Title |
---|
Ferreira G N M等人.Downstream processing of plasmid DNA for gene therapy andDNA vaccine applications.Trends in Biotechnology18 9.2000,18(9),383-385. |
Ferreira G N M等人.Downstream processing of plasmid DNA for gene therapy andDNA vaccine applications.Trends in Biotechnology18 9.2000,18(9),383-385. * |
解军等人.鱿鱼肝脏中大分子核酸的组成及分离纯化条件研究.中国药物与临床2 1.2002,2(1),7-9. |
解军等人.鱿鱼肝脏中大分子核酸的组成及分离纯化条件研究.中国药物与临床2 1.2002,2(1),7-9. * |
Also Published As
Publication number | Publication date |
---|---|
EP1713910A1 (de) | 2006-10-25 |
AU2005209389A1 (en) | 2005-08-11 |
WO2005073376A1 (de) | 2005-08-11 |
CN1914319A (zh) | 2007-02-14 |
EP1559783A1 (de) | 2005-08-03 |
US20070275920A1 (en) | 2007-11-29 |
JP2007519407A (ja) | 2007-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10619150B2 (en) | Methods and compositions for isolating small RNA | |
Ferreira et al. | Downstream processing of plasmid DNA for gene therapy and DNA vaccine applications | |
US6410274B1 (en) | Plasmid DNA purification using divalent alkaline earth metal ions and two anion exchangers | |
Urthaler et al. | Improved downstream process for the production of plasmid DNA for gene therapy | |
RU2719641C1 (ru) | Новые способы получения олигонуклеотидов | |
US5783686A (en) | Method for purifying nucleic acids from heterogenous mixtures | |
US6383393B1 (en) | Chromatographic purification and separation process for mixtures of nucleic acids | |
Kahn et al. | Purification of plasmid DNA by tangential flow filtration | |
EP1088064B1 (en) | Rapid and simple process for isolation of circular nucleic acids | |
JP4804347B2 (ja) | 固体支持体を使用してrnaを精製するための、組成物および方法 | |
US6180778B1 (en) | Process for the separation of double-stranded/single-stranded nucleic acid structures | |
US20100221788A1 (en) | Method for recovering short rna, and kit therefor | |
CN1914319B (zh) | 色谱分离核酸混合物的方法 | |
EP0827536A1 (en) | A method for large scale plasmid purification | |
US8029991B2 (en) | Method and formulation for the extraction of nucleic acids from any complex starting materials | |
Spector et al. | Polyadenylic acid on poliovirus RNA: IV. Poly (U) in replicative intermediate and double-stranded RNA | |
Guerrero-Germán et al. | Purification of plasmid DNA using tangential flow filtration and tandem anion-exchange membrane chromatography | |
US6800752B2 (en) | Chromatography material and a method using the same | |
WO2023031858A1 (en) | Plasmid dna purification methods | |
EP3303580B1 (en) | Electrophoresis assisted method for purifying a target nucleic acid using a delayed elution approach | |
CN115851702A (zh) | 一种适用于三代测序的高分子量基因组dna提取试剂盒 | |
KR101380909B1 (ko) | 핵산 정제용 흡착제 및 그 흡착제를 이용한 정제방법 | |
CN1142273C (zh) | 在交叉流动式离心机中纯化dna的方法 | |
KR101775790B1 (ko) | 핵산 분리 및 정제를 위한 세포용해 조성물 | |
Agbogbo et al. | Process Development for Plasmid DNA Production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: QIAGEN BIOENGINEERING (SHENZHEN) CO., LTD. Free format text: FORMER OWNER: QIAGEN GMBH Effective date: 20111031 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; TO: 517058 SHENZHEN, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20111031 Address after: 517058 Nanshan District hi tech Industrial Village, Guangdong, Shenzhen, R3-B, 6F&7F Patentee after: Cage Biological Engineering (Shenzhen) Co., Ltd. Address before: German Heerden Patentee before: Qiagen GmbH |